Qulipta Disease Interactions

Atogepant should be avoided in patients with severe hepatic impairment. For patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B), or severe hepatic impairment (Child-Pugh Class C), total atogepant exposure increased by 24%, 15%, and 38%, respectively. During clinical trials, cases of elevated transaminase levels to over 3 times the upper limit of normal were temporally associated with atogepant use; these cases were asymptomatic and resolved within 8 weeks of discontinuation.

Atogepant for the treatment of chronic migraine should be avoided in patients with severe renal dysfunction. No dose adjustment is needed in patients with mild or moderate renal dysfunction.